Lambda light chain deposition disease in a renal allograft

被引:14
|
作者
Tanenbaum, ND
Howell, DN
Middleton, JP
Spurney, RF
机构
[1] Duke Univ, Med Ctr, Dept Pathol, Durham, NC 27710 USA
[2] Durham VA Med Ctr, Durham, NC USA
关键词
D O I
10.1016/j.transproceed.2005.10.030
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Light chain deposition disease (LCDD) of the kidney is characterized by deposition of monoclonal light chains predominantly in glomeruli and in tubular basement membranes. The disease is frequently associated with a lymphoproliferative disorder, and the majority of cases are caused by deposition of kappa light chains. Although the occurrence of de novo multiple myeloma after renal transplantation is uncommon, there are several reports of LCDD involving renal allografts, either de novo or in patients with a diagnosis of LCDD prior to transplantation. To the best of our knowledge, all previously described cases in allografts have been in patients with kappa chain deposition. The relative importance of intrinsic properties of the kidney in predisposing to either kappa or lambda light chain deposition is not known. We present a case of LCDD caused by deposition of lambda light chains in a patient who received a cadaveric renal transplant.
引用
收藏
页码:4289 / 4292
页数:4
相关论文
共 50 条
  • [41] Enlightening light chain deposition disease
    Merlini, Giampaolo
    Palladini, Giovanni
    BLOOD, 2015, 126 (26) : 2770 - 2771
  • [42] κ light chain deposition disease of the liver
    Girelli, CM
    Lodi, G
    Rocca, F
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 1998, 10 (05) : 429 - 430
  • [43] PULMONARY LIGHT CHAIN DEPOSITION DISEASE
    Runnstrom, Martin
    Schimmel, Matt
    Van Nostrand, Keriann
    CHEST, 2020, 158 (04) : 1581A - 1581A
  • [44] LIGHT CHAIN DEPOSITION DISEASE: WHAT?
    Soller, Dylan
    Musco, Kaitlyn
    Strobel, Richard
    CHEST, 2021, 160 (04) : 1227A - 1227A
  • [45] Clinicopathologic Significance of Predominant Lambda Light Chain Deposition in IgA Nephropathy
    Ravipati, Prasanth
    Freese, Rebecca L.
    Royal, Virginie
    Bu, Lihong
    Canetta, Pietro
    Gipson, Debbie
    Kallash, Mahmood
    Kiryluk, Krzysztof
    Nast, Cynthia
    Reich, Heather N.
    Rheault, Michelle N.
    Saha, Manish
    Nachman, Patrick H.
    KIDNEY INTERNATIONAL REPORTS, 2022, 7 (11): : 2462 - 2473
  • [46] SYSTEMIC-LAMBDA LIGHT-CHAIN DEPOSITION IN A PATIENT WITH MYELOMA
    GANEVAL, D
    NOEL, LH
    DROZ, D
    LEIBOWITCH, J
    BRITISH MEDICAL JOURNAL, 1981, 282 (6265): : 681 - 683
  • [47] Recurrence of light chain deposit disease after renal allograft transplantation: potential role of rituximab?
    Kuypers, Dirk R. J.
    Lerut, Evelyne
    Claes, Kathleen
    Evenepoel, Pieter
    Vanrenterghem, Yves
    TRANSPLANT INTERNATIONAL, 2007, 20 (04) : 381 - 385
  • [48] KAPPA-LIGHT CHAIN DISEASE AND LAMBDA-LIGHT CHAIN DISEASE - SURVIVAL RATES AND CLINICAL MANIFESTATIONS
    SHUSTIK, C
    BERGSAGEL, DE
    PRUZANSKI, W
    BLOOD, 1976, 48 (01) : 41 - 51
  • [49] APPARENT RENAL RESPONSE TO MELPHALAN AND PREDNISONE (MP) IN LIGHT CHAIN DEPOSITION DISEASE (LCDD)
    HEILMAN, RL
    HOLLEY, K
    OFFORD, K
    VELOSA, J
    KYLE, R
    KIDNEY INTERNATIONAL, 1989, 35 (01) : 209 - 209
  • [50] Lenalidomide as a Beneficial Treatment Option for Renal Impairment Caused by Light Chain Deposition Disease
    Kimura, Satoshi
    Ohkawara, Hiroshi
    Ogawa, Kazuei
    Tanaka, Mizuko
    Sano, Takahiro
    Harada-Shirado, Kayo
    Takahashi, Hiroshi
    Ueda, Koki
    Shichishima-Nakamura, Akiko
    Matsumoto, Hayato
    Ikeda, Kazuhiko
    Kazama, Junichiro James
    Hashimoto, Yuko
    Ikezoe, Takayuki
    INTERNAL MEDICINE, 2018, 57 (24) : 3651 - 3657